SLC1A5 and metastatic malignant neoplasm in the lymph nodes: In HNSCC, SLC1A5, SLC7A5, and SLC7A11 were found in 59%, 61%, and 21% of patients, respectively, and SLC1A5 and SLC7A5 expression was significantly associated with staging, lymph node metastasis, lymphatic infiltration, and cell proliferation, while SLC7A11 expression was significantly associated with advanced stage and tumor factors [65].